Properties of tissue-engineering polycaprolactone matrices impregnated by VEGF and bFGF growth factors

Cover Page

Cite item


A contemporary approach to small vascular conduits design for bypass surgery is growing them in vivo using tissue-engineered biodegradable polymer scaffolds. The study assessed the possibility to use grafts made by two-phase electrospinning out of polycaprolactone with impregnated VEGF and bFGF. The scaffolds were tested for the alterations in physical, mechanical and biological properties after their impregnation with the growth factors. An increase in polymer graft strength was observed following their impregnation with VEGF and bFGF. ELISA showed a prolonged biomolecule release out of the scaffold within up to 3 weeks. The results of subcutaneous implantation of the scaffolds to Wistar rats demonstrated that the biological activity of VEGF and bFGF is preserved after their release into the surrounding tissues. Thus, the study showed that there is a possibility to use PCL scaffolds with VEGF and bFGF to design small vascular tissue- engineered grafts.

Full Text

Restricted Access

About the authors

V. V Sevostyanova

Institute for Complex Problems of Cardiovascular Disease of SB RAMS, Kemerovo

Y. L Elgudin

Case Western Reserve University, Cleveland, USA

G. E Wnek

Case Western Reserve University, Cleveland, USA

T. Lubysheva

Case Western Reserve University, Cleveland, USA

S. Emancipator

Case Western Reserve University, Cleveland, USA

A. S Golovkin

Institute for Complex Problems of Cardiovascular Disease of SB RAMS, Kemerovo

L. S Barbarash

Institute for Complex Problems of Cardiovascular Disease of SB RAMS, Kemerovo


  1. Taylor L.M., Edwards J.M., Porter J.M. Present status of reversed vein bypass grafting: five-year results of modern series. J. Vasc. Surg. 1990; 11: 193-205.
  2. Бокерия Л.А., Беришвили И.И., Солнышков Л.Э. и др. Повторные операции у больных ишемической болезнью сердца - современное состояние проблемы. Бюллетень НЦССХ им. Бакулева РАМН. 2009; 10(3): 5-27.
  3. Cooper K., Chun I., Colter D., inventors; Ethicon Inc., assignee. Tissue engineered blood vessels. US patent 0,275,129. 2009 Nov 5.
  4. Tillman B., Yazdani S., Lee S. et al. The in vivo stability of electrospun polycaprolactone-collagen scaffolds in vascular reconstruction. Biomaterials 2009; 30: 583-8.
  5. Schantz J.T., Chim H., Whiteman M. Cell guidance in tissue engineering: SDF-1 mediates site-directed homing of mesenchymal stem cells within three-dimensional polycaprolactone scaffolds. Tissue Eng. 2007; 13(11): 2615-24.
  6. Kim K., Luu Y., Chang C. et al. Incorporation and controlled release of a hydrophilic antibiotic using poly(lactide-coglycolide)-based electrospun nanofibrous scaffolds. J. Controll. Release. 2004; (98): 47-56.
  7. Verreck G., Chun I., Rosenblatt J. et al. Incorporation of drugs in an amorphous state into electrospun nanofibers composed of a water- insoluble, nonbiodegradable polymer. J. Controll. Release. 2003; 92: 349-60.
  8. Sokolsky-Papkov M., Agashi K., Olaye A. et al. Polymer carriers for drug delivery in tissue engineering. Advanced Drug Delivery Reviews. 2007; (59): 187-206.
  9. Hakkarainen M. Aliphatic Polyesters: Abiotic and biotic degradation and degradation products. Advances in Polymer Science. 2002; 157: 113-8.
  10. Sahoo R., Sahoo S., Sahoo S. et al. Synthesis and characterization of polycaprolactone - gelatin nanocomposites for control release anticancer drug paclitaxel. Euro. J. Sci. Res. 2011; 48(3): 527-37.
  11. Zhu X., Eng M., Tabata Y. et al. Delivery of basic fibroblast growth factor from gelatin microsphere scaffold for the growth of human umbilical vein endothelial cells. Tissue Engineering: Part A. 2008; 14(12): 1939-47.
  12. Thevenot P., Nair A., Shen J. et al. The effect of incorporation of SDF-1a into PLGA scaffolds on stem cell recruitment and the inflammatory response. Biomaterials 2010; 31(19): 3997-4008.
  13. Sharon J.L., Puleo D.A. Immobilization of glycoproteains, such as VEGF, on biodegradable substrates. Acta Biomater. 2008; 4(4): 1016-23.
  14. Sun Q., Chen R., Shen Y. et al. Sustained vascular endothelial growth factor delivery enhances angiogenesis and perfusion in ischemic hind limb. Pharm. Res. 2005; 22(7): 1110-16.
  15. Guan J., Stankus J., Wagner W. Biodegradable elastomeric scaffolds with basic fibroblast growth factor release. J. Controll. Release. 2007; 120(1-2): 70-8.
  16. Layman H., Spiga M., Brooks T. et al. The effect of the controlled release of basic fibroblast growth factor from ionic gelatin- based hydrogels on angiogenesis in a murine critical limb ischemic model. Biomaterials 2007; 28(16): 2646-54.
  17. Wang Y. Liu X.-C., Zhao J. et al. Degradable PLGA scaffolds with basic fibroblast growth factor. Texas Heart Institute Journal 2009; 36(2): 89-97.
  18. Losi P., Briganti E., Magera A. et al. Tissue response to poly(ether)urethane-polydimethylsiloxane-fibrin composite scaffolds for controlled delivery of pro-angiogenic growth factors. Biomaterials 2010; 31(21): 5336-44.
  19. Bolgen N., Menceloglu Y.Z., Acatay K. et al. In vitro and in vivo degradation of non-woven materials made of poly(e-caprolactone) nanofibers prepared by electrospinning under different conditions. J. Biomat. Sci. Polym. Edit. 2005; 16(12): 1537-55.
  20. Ramakrishna S., Fujihara K., Teo W. et al. An introduction to electrospinning and nanofibers. Singapore: World Scientific; 2005.
  21. Cui W., Zhou Y., Chang J. Electrospun nanofibrous materials for tissue engineering and drug delivery. Sci. Technol. Adv. Mater. 2010; (11): 1-11
  22. Zong X., Ran S., Kim K.-S. et al. Structure and morphology changes during in vitro degradation of electrospun poly(glycolide- co-lactide) nanofibre membrane. Biomacromolecules 2003; (4): 416-23.
  23. Smith M. Biologicaly functional scaffolds for tissue engineering and drug delivery, produced through electrostatic processing [dissertation]. Cleveland (OH): Case Western Reserve Univ.; 2010.
  24. Mandriota S.J., Pepper M.S. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J. Cell Sci. 1997; 110: 2293-302.

Copyright (c) 2012 PJSC Human Stem Cells Institute

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 57156 от 11.03.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies